PREDICTING MEASURABLE RESIDUAL DISEASE FOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS POSTTRANSPLANTATION

被引：0
|
作者：
Wang, Yue-Wen [1 ,2 ]
Fu, Guo-Mei [1 ,2 ]
Xu, Lan-Ping [1 ,2 ]
Wang, Yu [1 ,2 ]
Cheng, Yi-Fei [1 ,2 ]
Zhang, Yuan-Yuan [1 ,2 ]
Zhang, Xiao-Hui [1 ,2 ]
Liu, Yan-Rong [1 ,2 ]
Liu, Kai-Yan [1 ,2 ]
Huang, Xiao-Jun [1 ,2 ]
Chang, Ying-Jun [1 ,2 ]
机构：
[1] Peking Univ Peoples Hosp, Beijing, Peoples R China
[2] Peking Univ Inst Hematol, Beijing, Peoples R China
来源：
BONE MARROW TRANSPLANTATION | 2024年 / 59卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P516
引用
收藏
页码：498 / 498
页数：1
相关论文
共 50 条
  • [31] Current assessment and management of measurable residual disease in patients with acute lymphoblastic leukemia in the setting of CAR-T-cell therapy
    Lin Minghao
    Zhao Xiaosu
    Chang Yingjun
    Zhao Xiangyu
    中华医学杂志英文版, 2024, 137 (02)
  • [32] Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia
    Bazinet, Alexandre
    Kadia, Tapan M.
    Short, Nicholas
    Borthakur, Gautam
    Wang, Sa A.
    Loghavi, Sanam
    Jorgensen, Jeffrey L.
    Patel, Keyur P.
    DiNardo, Courtney D.
    Daver, Naval
    Alvarado, Yesid
    Haddad, Fadi
    Pierce, Sherry A.
    Nogueras Gonzalez, Graciela M.
    Maiti, Abhishek
    Andreeff, Michael
    Jabbour, Elias
    Konopleva, Marina
    Huang, Xuelin
    Kantarjian, Hagop
    Ravandi, Farhad
    BLOOD, 2022, 140 : 2267 - 2269
  • [33] Monitoring Measurable Residual/Relapsing Disease after Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia
    Wethmar, K.
    Matern, S.
    Esseling, E.
    Bruggemann, M.
    Schliemann, C.
    Berdel, W. E.
    Lenz, G.
    Stelljes, M.
    ANNALS OF HEMATOLOGY, 2019, 98 : S57 - S57
  • [34] METHODS FOR THE MINIMUM RESIDUAL DISEASE MONITORING IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
    Parovichnikova, E. N.
    Mavrina, E. S.
    Surin, V. L.
    Savchenko, V. G.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2013, 58 (03): : 45 - 48
  • [35] Updates on lymphoblastic leukemia/lymphoma classification and minimal/ measurable residual disease analysis
    Kovach, Alexandra E.
    Wood, Brent L.
    SEMINARS IN DIAGNOSTIC PATHOLOGY, 2023, 40 (06) : 457 - 471
  • [36] Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia
    Roug, Anne Stidsholt
    Ommen, Hans Beier
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (04)
  • [37] Perspective on measurable residual disease testing in acute myeloid leukemia
    Walter, Roland B.
    LEUKEMIA, 2024, 38 (01) : 10 - 13
  • [38] Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia
    Anne Stidsholt Roug
    Hans Beier Ommen
    Current Treatment Options in Oncology, 2019, 20
  • [39] Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia
    Azenkot, Tali
    Jonas, Brian A.
    CANCERS, 2022, 14 (15)
  • [40] Improved detection of measurable residual disease in acute myeloid leukemia
    Zhang, Xuan
    Grimes, H. Leighton
    SCIENCE ADVANCES, 2023, 9 (38)
12345